Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 10/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548246 | 0.94 | UTS2R (0.47) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5547260 | 0.88 | UTS2R (0.50) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5548966 | 0.85 | UTS2R (0.47) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5547628 | 0.82 | UTS2R (0.48) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5547240 | 0.82 | UTS2R (0.46) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL5541293 | 0.81 | UTS2R (0.45) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4862040 | 0.80 | UTS2R (0.66) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL3557619 | 0.80 | UTS2R (0.44) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL3557622 | 0.80 | UTS2R (0.44) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL3560776 | 0.78 | UTS2R (0.46) | UTS2RADRA2ADRD2SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | UTS2R 636/4885ADRA2A 30/4885DRD2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.